Showing results (151-160 of 156) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 156 results.
BMC Medicine|October 25, 2022
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trialDan Liu, Jun Zhou, Yongsheng Wang, et al.
The Lancet. Oncology|September 8, 2022
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trialWeijie Gu, Weiqing Han, Hong Luo, et al.
The Lancet. Oncology|October 30, 2025
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Josep Piulats, Tilman Todenhöfer, et al.
The Lancet. Oncology|December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trialKarim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphomaDan Liu, Chunguang Ma, Ping Lu, et al.
Chinese Medical Journal|April 3, 2023
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trialChengyuan Gu, Zengjun Wang, Tianxin Lin, et al.
Pageof 16